Use of composite endpoints in clinical trials

Statistics in Medicine

Volumn 33, Issue 27, 2014, Pages 4709-4714

  Sankoh, Abdul J ^a   Li, Haihong ^a   D'Agostino, Ralph B ^b  

^a VERTEX PHARMACEUTICALS   (United States)

^b BOSTON UNIVERSITY   (United States)

Author keywords

Clinical relevance; Clinical utility; Flexible statistical approaches; Single primary endpoint; Types of endpoints

Indexed keywords

ARTICLE; CAUSE OF DEATH; CLINICAL DECISION MAKING; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); DRUG SCREENING; HEALTH ECONOMICS; HUMAN; INFORMATION PROCESSING; MEASUREMENT PRECISION; RESEARCH ETHICS; SAMPLE SIZE; SENSITIVITY AND SPECIFICITY; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; BIOASSAY; BIOMETRY; MORTALITY; PROCEDURES;

BIOMETRY; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION; ENDPOINT DETERMINATION; HUMANS; MORTALITY; TREATMENT OUTCOME;

EID: 84939268682     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.6205     Document Type: Article

References (30)

1. Committee for Proprietary Medicinal Products. Points to consider on multiplicity issues in clinical trials, 2002. (Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003640.pdf) [Accessed on May 12, 2014].
2. Chi GYH. Some issues with composite endpoints in clinical trials. Fundamental & Clinical Pharmacology 2005; 19: 609-619.
3. Moyé LA. Multiple Analyses in Clinical Trials. Springer-Verlag: New York, 2003.
4. Lubsen J, Kirwan BA. Combined endpoints: can we use them? Statistics in Medicine 2002; 21: 2959-2970.
5. Cannon CP. Perspectives on composite endpoints. Controlled Clinical Trials 1997; 18: 517-529.
6. Sankoh AJ. An overview of strategies for dealing with composite endpoints in clinical trials, 2003 ASA Proceedings, Biopharmaceutical section, 2003; 334-338.
7. Sankoh AJ, D'Agostino RB, Huque MF. Efficacy endpoint selection and multiplicity adjustment methods in clinical trials with inherent multiple endpoint issues. Statistics in Medicine 2003; 22: 3133-3150.
8. Gidda S, Tejani A. All for one, one for all: evaluating composite endpoints in clinical trials. Research Brief 2008; 141: 28-31.
9. Freemantle N, Calvert M, Wood J, Eastaugh J, Griffin C. Composite outcomes in randomized trials: greater precision but with greater uncertainty? Journal of the American Medical Association 2003; 289: 2554-9.
10. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003.
11. Huque MF, Alosh M, Bhore F. Addressing multiplicity issues of a composite endpoint and its components in clinical trials. Journal of Biopharmaceutical Statistics 2011; 21: 610-634.
12. Makaig SJ, Kelly D, The U.S. Multicenter FK506 Liver Study Group. A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppressant in liver transplantation. New England Journal of Medicine 1994; 331: 1110-1115.
13. Räisänen-Sokolowski A, Vuoristo P, Myllärniemi M, Yilmaz S K E, Häyry P. Mycophenolate mofetil (MMF, RS-61443) inhibits inflammation and smooth muscle cell proliferation in rat aortic allografts. Transplant Immunology 1995; 4: 342-351.
14. Bolognese JA, Ehrich EW, Schnitzer TJ. Precision of composite measures of osteoarthritis efficacy in comparison to that of individual endpoints. The Journal of Rheumatology 2001; 28: 2700-2704.
15. Hallstrom AP, Litwin P E, Weaver W D. A method of assigning scores to the components of a composite outcome: an example from the MITI trial. Controlled Clinical Trials 1992; 13: 148-155.
16. O'Brien PC. Procedures for comparing samples with multiple endpoints. Biometrics 1984; 40: 1079-1089.
17. Pocock SJ, Geller NL, Tsiatis AA. The analysis of multiple endpoints in clinical trials. Biometrics 1987; 43: 487-498.
18. Röhmel J, Gerlinger C, Benda N, Läuter J. On testing simultaneously noninferiority in two multiple primary endpoints and superiority in at least one of them. Biometrical Journal 2006; 48: 916-933.
19. Dmitrienko A, Bretz F, Westfall PH, Troendle J, Wiens BL, Tamhane AC, Hsu JC. Multiple Testing Methodology. Multiple Testing Problems in Pharmaceutical Statistics. Chapman and Hall/CRC Press: New York, 2009.
20. Huque MF, Alosh M. A flexible fixed-sequence testing method for hierarchically ordered correlated multiple endpoints in clinical trials. Journal of Statistical Planning and Inference 2008; 138: 321-35.
21. Alosh M, Huque MF. A flexible strategy for testing subgroups and overall population. Statistics in Medicine 2009; 28: 3-23.
22. Wiens BL. A fixed sequence Bonferroni procedure for testing multiple endpoints. Pharmaceutical Statistics 2003; 2: 211-15.
23. Wiens BL, Dmitrienko A. The fallback procedure for evaluating a single family of hypotheses. Journal of Biopharmaceutical Statistics 2005; 15: 929-42.
24. Li J, Mehrotra DV. An efficient method for accommodating potentially under powered primary endpoints. Statistics in Medicine 2008; 27: 5377-5391.
25. Alosh M, Huque MF. A consistency-adjusted alpha-adaptive strategy for sequential testing. Statistics in Medicine 2010; 29: 1559-1571.
26. Zhao YD, Dmitrienko A, Tamura R. Design and analysis considerations in clinical trials with a sensitive subpopulation. Statistics in Biopharmaceutical Research 2010; 2: 72-83.
27. Li H, Sankoh AJ, D'Agostino RB. Extension of adaptive alpha allocation methods for strong control of the family-wise error rate. Statistics in Medicine 2013; 30;32(2):181-95.
28. Millen BA, Dmitrienko A. Chain procedures: a class of flexible closed testing procedures with clinical trial applications. Statistics in Biopharmaceutical Research 2011; 3: 14-30.
29. Dmitrienko A, D'Agostino RB, Huque MF, 2013. Key multiplicity issues in clinical drug development. Statistics in Medicine 32: 1079-1111.
30. Dmitrienko A, D'Agostino RB. Tutorial in biostatistics: traditional multiplicity adjustment methods in clinical trials. Statistics in Medicine 2013; 32: 5172-5218.